Cytokinetics (CYTK) Other Accumulated Expenses (2012 - 2026)

Cytokinetics (CYTK) has reported Other Accumulated Expenses for 15 consecutive years, with $8.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 47.58% year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $8.6 million (up 47.58% YoY), while the FY2025 annual figure was $3.8 million, down 42.13% from the prior year.
• Other Accumulated Expenses advanced to $8.6 million in Q1 2026 per CYTK's latest filing, from $3.8 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $14.8 million in Q1 2024 and bottomed at $2.0 million in Q3 2025.
• Historically, Other Accumulated Expenses has averaged $7.8 million across 5 years, with a median of $6.6 million in 2024.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses soared 666.14% — and 2025, when it sank 64.04%.
• Cytokinetics' Other Accumulated Expenses stood at $6.2 million in 2022, then soared by 69.65% to $10.6 million in 2023, then plunged by 37.27% to $6.6 million in 2024, then slumped by 42.13% to $3.8 million in 2025, then soared by 124.16% to $8.6 million in 2026.
• Business Quant data shows CYTK's Other Accumulated Expenses at $8.6 million in Q1 2026, $3.8 million in Q4 2025, and $2.0 million in Q3 2025.